South Texas Money Management Ltd. lifted its position in GlaxoSmithKline plc (NYSE:GSK) by 5.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 754,696 shares of the pharmaceutical company’s stock after acquiring an additional 38,708 shares during the period. South Texas Money Management Ltd.’s holdings in GlaxoSmithKline were worth $31,539,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in GSK. Bank of New York Mellon Corp increased its position in GlaxoSmithKline by 1,788.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,306,091 shares of the pharmaceutical company’s stock valued at $92,636,000 after buying an additional 2,183,983 shares in the last quarter. Boston Partners bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $65,234,000. Morgan Stanley increased its position in GlaxoSmithKline by 16.5% during the 3rd quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock valued at $169,232,000 after buying an additional 597,367 shares in the last quarter. Norges Bank bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $17,275,000. Finally, Two Sigma Investments LP bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $15,936,000. 11.08% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on GSK shares. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 2nd. BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. Exane BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. UBS Group lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Friday, February 22nd. Finally, Shore Capital lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $41.99.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 6th. The pharmaceutical company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.09. The business had revenue of $10.55 billion during the quarter, compared to analyst estimates of $9.85 billion. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. On average, equities research analysts forecast that GlaxoSmithKline plc will post 2.91 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd were issued a $0.597 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date was Thursday, February 21st. This represents a $2.39 dividend on an annualized basis and a dividend yield of 5.90%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 75.32%.
COPYRIGHT VIOLATION NOTICE: “South Texas Money Management Ltd. Increases Stake in GlaxoSmithKline plc (GSK)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2019/04/16/south-texas-money-management-ltd-increases-stake-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: How to trade on quiet period expirations
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.